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Implication of the glutamate–cystine antiporter xCT in
schizophrenia cases linked to impaired GSH synthesis
M. Fournier1, A. Monin1, C. Ferrari1, P. S. Baumann1,2, P. Conus2 and K. Do1
xCT is the speciﬁc chain of the cystine/glutamate antiporter, which is widely reported to support anti-oxidant defenses in vivo. xCT
is therefore at the crossroads between two processes that are involved in schizophrenia: oxidative stress and glutamatergic
neurotransmission. But data from human studies implicating xCT in the illness and clarifying the upstream mechanisms of xCT
imbalance are still scarce. Low glutathione (GSH) levels and genetic risk in GCLC (Glutamate–Cysteine Ligase Catalytic subunit), the
gene of limiting synthesizing enzyme for GSH, are both associated with schizophrenia. In the present study, we aimed at
determining if xCT regulation by the redox system is involved in schizophrenia pathophysiology. We assessed whether modulating
GCLC expression impact on xCT expression and activity (i) in ﬁbroblasts from patients and controls with different GCLC genotypes
which are known to affect GCLC regulation and GSH levels; (ii) in rat brain glial cells, i.e., astrocytes and oligodendrocytes, with a
knock-down of GCLC. Our results highlight that decreased GCLC expression leads to an upregulation of xCT levels in patients’
ﬁbroblasts as well as in astrocytes. These results support the implication of xCT dysregulation in illness pathophysiology and further
indicate that it can result from redox changes. Additionally, we showed that these anomalies may already take place at early stages
of psychosis and be more prominent in a subgroup of patients with GCLC high-risk genotypes. These data add to the existing
evidence identifying the inﬂammatory/redox systems as important targets to treat schizophrenia already at early stages.
npj Schizophrenia  (2017) 3:31 ; doi:10.1038/s41537-017-0035-3
INTRODUCTION
The system xc- is a sodium-independent antiporter, which imports
cystine and exports glutamate in a 1:1 ratio.1 Intracellular cystine is
readily reduced to cysteine, the limiting precursor for glutathione
(GSH) synthesis. Accordingly, xc- is widely reported to support
anti-oxidant defenses in vivo.2,3 xc- is a heterodimer formed by the
association of xCT (coded by SLC7A11) and 4F2hc (SLC3A2). xCT is
the speciﬁc chain and an increase of gene expression often
reﬂects an enhancement of cystine transport.3–5 xCT is stabilized
at the membrane by CD44, a receptor for hyaluronic acid, whose
expression increases intracellular levels of cysteine and GSH.6
Oxidative stress induces the expression of xCT.2,3 The transcrip-
tion factor Nrf2 is well described as a master regulator for the up-
regulation of genes in response to oxidative stress.7 In basal
conditions, Keap1 binds to Nrf2 and promotes its degradation by
the ubiquitin-proteasome system.8 In case of oxidative stress,
Keap1 dissociates, allowing Nrf2 accumulation, translocation to
the nucleus, and binding to antioxidant response elements (ARE)
in the promoter regions of target genes.9–11 The promoter of
SLC7A11 contains four ARE12,13 and activation of SLC7A11
expression by oxidation depends on Nrf2 as shown in Nrf2-/-
mice.12 The Nrf2 inducer tert-butyl-hydroquinone (tBHQ), as well
as the inhibitor of GSH synthesis buthionine sulfoximine (BSO),
robustly increase xCT protein levels in cell culture.14,15
xCT expression is high in the brain16,17 where it is expressed by
astrocytes18 while mature neurons show no or little expression.2,18
xCT in rodent brain modulates extracellular glutamate levels
through non vesicular release: over half of the non synaptic
release of glutamate is attributed to the antiporter.19–21 Changes
in xCT levels are linked to many neurological and psychiatric
disorders, including schizophrenia based on two human stu-
dies.3,22,23 In 'postmortem' tissue of dorso lateral-prefrontal cortex,
xCT protein levels are increased in schizophrenia patients
compared to control individuals.24 A recent study reported that
SLC7A11 gene expression is decreased compared to controls in
peripheral white blood cells from Chinese Han patients.25 The
authors of both studies excluded a confounding effect of
antipsychotic treatment but did not identify potential upstream
pathways which may lead to xCT impairment in patients.
Mounting evidence suggests oxidative stress and impairment of
fast-spiking GABAergic interneurons as interdependent mechan-
isms forming a hub in schizophrenia physiopathology on which
genetic and environmental factors converge.26–28 Many studies
revealed markers of oxidative stress in patients, both in the brain
and in peripheral samples such as blood or ﬁbroblasts.29 In line
with these observations, levels of the anti-oxidant defenses differ
between patients and control individuals.30 These data indicate
that induction of the response to oxidative stress, despite being
present to some extent, is not efﬁciently regulated in patients. The
gene coding for the limiting enzyme for GSH synthesis (GCLC;
Glutamate-Cysteine Ligase Catalytic subunit) was associated with
schizophrenia and variants of the tri-nucleotide repeat poly-
morphism in GCLC were more frequent in schizophrenia patients
than in controls (GCLC high-risk genotypes).31 The GCLC high-risk
genotypes are associated with a decrease of GSH levels in medial
prefrontal cortex32 and in ﬁbroblasts.31 Moreover a metabolomic
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study with patients’ ﬁbroblasts showed altered reactivity to
oxidative stress in GCLC high-risk genotypes.33
Therefore xCT is at the crossroads between oxidative stress and
glutamatergic neurotransmission, two processes that are involved
in schizophrenia. But data from human studies implicating xCT in
the illness are still scarce, and the upstream mechanisms leading
to xCT imbalance deserve further clariﬁcation. We hypothesize
that oxidative stress induces xCT function, which subsequently
participates in the dysregulation of glutamatergic signaling. In the
present study, we aimed at determining if xCT regulation by the
redox system is involved in schizophrenia physiopathology. First,
we used ﬁbroblasts from patients and controls to assess the
impact of GCLC high-risk genotypes on xCT expression and
activity, either in control conditions or by tBHQ-induced anti-
oxidant response. Second, we investigated whether impairment of
GCLC expression may alter xCT function in rat brain glial cells,
astrocytes and oligodendrocytes.
RESULTS
GCLC high-risk genotypes are associated with increased levels of
xCT mRNA.
Fibroblasts from schizophrenia patients or control individuals, with
GCLC high-risk or GCLC low-risk genotypes (Table 1), were treated
or not by tBHQ. Gene expression was assessed by microarray in
vehicle and in tBHQ-treated conditions.
In the top ﬁve genes that were up-regulated by tBHQ both in
patients and controls, SLC7A11 (coding for xCT) expression
showed a 7.9-fold increase (false discovery rate for paired
comparisons, FDR < 1.10−21, Fig. 1a). Expression of the gene
SLC3A2 (coding for 4F2hc) was also increased by tBHQ, suggesting
an overall enhancement of amino-acid uptake (fold change, FC =
3.10; FDR = 1.10−20).
Levels of SLC7A11 and SLC3A2 were similar between patients
and controls both in vehicle (FC = −1.03; p-value = 0.85; FC = 1.04;
p-value = 0.73) and tBHQ-treated condition (FC = 1.06; p-value =
0.72, FC = 1.04; p-value = 0.70).
When comparing individuals (patients and controls) with GCLC
high-risk and GCLC low-risk genotypes, SLC7A11 was the most up-
regulated gene associated with GCLC high-risk variants, with a 2-
fold increase of expression already at basal level (p-value =
1.2,10−5, Fig. 1b). Expression of the subunit SLC3A2 was not
modiﬁed (FC = 1.22; p-value = 0.08), however the gene CD44 was
slightly increased (FC = 1.16; p-value = 0.002). For SLC7A11, the
interaction between tBHQ treatment and genotype was signiﬁcant
(t = -3.81; p-value = 0.0004); examining the means of expression
indicates that the up-regulation in response to tBHQ was less in
the GCLC high-risk genotypes than in the GCLC low-risk genotypes
(Fig. 1c).
Altogether these data indicated that regulation of xCT
expression was altered in individuals with GCLC high-risk
genotypes. Therefore GCLC high-risk schizophrenia patients may
represent a distinct subgroup with more pronounced anomalies of
xCT regulation than GCLC low-risk patients. In a next step, we
aimed at validating this ﬁnding at the functional level in early
psychosis patients. In order to maximize the power and to avoid
bias due to sex, we analyzed only male early psychosis patients.
GCLC high-risk genotypes are associated with increased cystine
uptake
We quantiﬁed cystine uptake by xc- system in ﬁbroblasts from
GCLC low-risk, high-risk early psychosis patients and age-matched
GCLC low-risk controls (Table 2), in vehicle and tBHQ treated
conditions.
In vehicle conditions, cystine uptake was higher in GCLC high-
risk patients than in GCLC low-risk patients and GCLC low-risk
Table 1. Demographics for the microarray study
Patients Controls
GCLC Low-risk High-risk Low-risk High-risk
n= 10 10 15 5
Age in years (s.d) 30.3 (2.2) 36.7 (4) 38.9 (2.3) 28.8 (2.7)
Sex (males/females) 6 / 4 7 / 3 9 / 6 2 / 3
Diagnostic
Schizophrenia 9 6 – –
Schizo-affective – 2 – –
Schizotype 1 1 – –
Medication in CPZ 80 (20) 79 (44) – –
s.d. standard deviation
Fig. 1 SLC7A11 expression in skin ﬁbroblasts with GCLC high-risk or
GCLC low-risk genotypes: Top-5 genes up-regulated in ﬁbroblasts
treated by tBHQ versus vehicle (a), and up-regulated in ﬁbroblasts
with GCLC high-risk versus GCLC low-risk genotypes (b) both in
patients and controls. FC fold of change, FDR false discovery rate
(paired comparisons). c Plot illustrating microarray data for SLC7A11.
Data are represented as mean± standard error of the mean
Table 2. Demographics for the uptake experiments
Patients Controls
GCLC Low-risk High-risk Low-risk
n= 11 8 9
Age in years (s.d) 22.6 (3.5) 22.3 (3.2) 23.5 (3.6)
Sex (males/females) 11 / 0 8 / 0 9 / 0
Diagnostic
Schizophrenia 9 6 –
Schizo-affective 1 1 –
Schizophreniform 1 1 –
Illness duration in years (sd) 3.8 (3.2) 2.0 (1.2) –
Medication in CPZ 303 (247) 301 (265) –
s.d. standard deviation, CPZ chlorpromazine equivalents
Upregulation of xc- activity in schizophrenia
M Fournier et al.
2











controls (respectively 1.4-fold; p = 0.010 and 1.2-fold; p = 0.041, see
Fig. 2a). The uptake was inhibited by the addition of glutamate or
by the xCT inhibitor sulfasalazine, therefore indicating the
speciﬁcity of the measurements (Supplementary Fig. 1). As
expected, treatment with tBHQ increased cystine uptake by 4-
fold (p < 0.01). The tBHQ-induced cystine uptake was comparable
for the three groups. After tBHQ treatment, cystine uptake
remained higher in GCLC high-risk patients compared with GCLC
low-risk controls (1.6-fold; p = 0.040, Fig. 2b), but not compared
with GCLC low-risk patients. Cystine uptake was not correlated
with the levels of anti-psychotic treatment (Supplementary Fig. 2).
Because regulation of xc- system may differ according to cell
types, we wanted to clarify whether these impairments are
relevant for speciﬁc brain cells.
GCLC down-regulation increases cystine uptake by astrocytes
Because xc- system is mostly present in astrocytes and not in
neurons,18 we assessed cystine uptake in glial cells from rat cortex
(oligodendrocyte progenitor cells (OPCs) and astrocytes). To
impair the regulation of GCLC, cells were transduced by lentivirus
to overexpress shRNA as previously described.34
Knock-down with shRNA decreased GCLC protein levels by 49%
in OPCs.34 OPCs had a slow uptake of cystine, which reached a
maximum after 30 min and was inhibited by the addition of
glutamate (Fig. 3). The knock-down of GCLC did not affect the level
of cystine uptake after 15 min (Fig. 3a) nor after 30 min compared
to either scrambled shRNA or non infected cells (Fig. 3b).
In dividing astrocytes, knock-down with shRNA decreased GCLC
mRNA by 27% (Fig. 4a). Cystine uptake was faster in astrocytes
than in OPCs, and was also inhibited by sulfasalazine (Fig. 4b).
After GCLC knock-down, the uptake was 1.6-fold higher than in
control conditions with scrambled shRNA, both after 1 and 5min
of uptake (Fig. 4b).
Primary astrocytes were also cultured with di-butyryl cyclic AMP
(dbcAMP) as dbcAMP-treated astrocytes may resemble more
closely the differentiated astrocytes present in brain tissue.35
Cyclic AMP induces morphological changes, stops cell division and
increases antioxidant defenses.35–37 dbcAMP-treated astrocytes
had a 6-fold higher uptake of cystine than dividing astrocytes (see
uptake at 5 min in Fig. 4b, c and consistent with previous
publications15,38). In dbcAMP-treated astrocytes, knock-down with
shRNA decreased GCLC mRNA by 46% (Fig. 4a). GCLC knock-down
in dbcAMP-treated astrocytes led to a 1.2-fold and 1.5-fold
increase of cystine uptake after 1 and 5min respectively
compared with scrambled shRNA (p = 0.028 and 0.045 respec-
tively; Fig. 4c).
DISCUSSION
We studied the regulation of xCT by genetic impairment of GSH
synthesis. We found that ﬁbroblasts with GCLC high-risk geno-
types, which are associated with lower brain GSH brain levels and
higher risk for schizophrenia31,32 displayed higher expression and
higher activity of xCT than ﬁbroblasts with GCLC low-risk
genotypes. The tBHQ-induced increase of cystine uptake
appeared to be similar across genotypes. In a translational
approach, we conﬁrmed that GCLC knock-down increased the
activity of xCT in primary culture of rodent astrocytes. We did not
observe the same response to GCLC knock-down in oligoden-
drocyte precursors, therefore underlining that xCT regulation by
GCLC levels was cell type dependent. Altogether, the results
indicate that impaired GSH synthesis leads to the upregulation of
xCT activity in speciﬁc glial cells, a mechanism already relevant to
early stages of schizophrenia.
These data add to the characterization of GCLC high-risk
genotypes. Previous works indicate that these high-risk geno-
types, without an additional oxidative stress, affect at least two
metabolic pathways in cultured ﬁbroblasts: the redox system31,33
and lysolipids levels.33 Importantly, the redox pathway is also
affected in blood39 and in the brain as shown by the 14% decrease
of GSH concentration in prefrontal cortex of GCLC high-risk
individuals.32 Here we show that the GCLC high-risk genotypes are
also associated with an increased activity of xCT in ﬁbroblasts.
Frequencies of GCLC high-risk genotypes are higher in schizo-
phrenia patients than in controls31 and vary with the ethnicity.40
Controlling for this confounding factor in case-control studies is
thus important as it may explain discrepancies between studies.
The decrease of GCLC expression (by genetic variants or by
knock-down) may increase xc- activity through the Nrf2 signaling
pathway. Indeed GCLC expression tightly controls GSH levels, and
the high-risk variants are associated with lower GSH.31,32 Deple-
tion of cysteine or GSH may lead to oxidative stress, to the
activation of Nrf2, and to the enhancement of xCT activity.12
Consistently, previous work showed that depletion of intracellular
cysteine or GSH enhanced the activity of the cystine-glutamate
antiporter.15,41 Although Nrf2 is the most studied antioxidant
regulator, other pathways may also be involved.15 For instance,
SLC7A11 promoter also contains binding sites for ATF4, a
Fig. 2 Cystine uptake by skin ﬁbroblasts: Cells were treated (a) with vehicle (0.05% DMSO) or (b) with tBHQ (50uM for 18 h) which induces the
anti-oxidant response. Internalized Cystine was assessed after 5 min of uptake. Data are represented as mean± standard error of the mean;
*p-value< 0.05
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transcription factor typically activated by amino acid starvation.42
Activation of ATF4 pathway up-regulates xCT, increases intracel-
lular GSH levels, and confers resistance to oxidative stress.43
An interesting downstream effect of enhanced xc- activity is the
increased efﬂux of glutamate, which may participate to schizo-
phrenia physiopathology by affecting the inhibitory/excitatory
balance.22 Glutamate levels in various brain regions are higher in
early psychosis patients than in matched healthy controls.44
Accordingly, impairment of glutamate transport has been
suggested by 'postmortem' brain studies of schizophrenia
patients.45,46 The upregulation of xCT may thus participate in
the impairment of glutamate transport and in the increase of brain
glutamate in schizophrenia. xc- activity has been shown to
signiﬁcantly affect glutamate levels as knock-out mice for Slc7a11
have decreased levels of extracellular glutamate.20,21 Gene
deletion leads to minor spatial memory deﬁcits,20,47 and impaired
hippocampal LTP47 and acute inhibition of xc- is associated with
anxiety-related behaviors.49 Inactivation of the glial glutamate
transporter GLAST, which likely leads to an increase of extracellular
glutamate, also leads to endophenotypes that are associated with
schizophrenia such as memory deﬁcits and impaired acoustic
startle.47
Interpretation of the results is limited by the use of rodent cells,
as it is not clear to which extent rat primary glial cells reﬂect
human brain physiology. Because xCT is induced by the higher O2
levels in culture compared to in vivo conditions,3 interpretation of
this work is limited by the in vitro setting. Nevertheless, regulatory
mechanisms of xCT expression have been largely deciphered by
studies using cell culture,1 thus highlighting that our conclusions
can be transposed to in vivo conditions. Moreover, our observa-
tion that OPCs did not display an increase of xCT function
following GCLC knock-down is also in favor of a speciﬁc regulation.
In conclusion, our data show that a decrease of GCLC
expression, the limiting synthesizing enzyme for GSH, leads to
an upregulation of xCT levels in patients’ ﬁbroblasts as well as in
astrocytes. These results from schizophrenia patients support the
emerging data involving xCT dysregulation in illness physio-
pathology and further indicate that it can result from redox
changes such as lower GSH levels, which have been previously
associated with schizophrenia. According to our results, xCT
dysregulation already takes place at early stages of psychosis and
is more prominent in a subgroup of patients with GCLC high-risk
genotypes. Investigating consequences of xCT dysregulation at
the clinical level would shed light on the symptoms that may
respond to molecules targeting the immune and/or redox system.
METHODS
Recruitment
All individuals were recruited in Lausanne area, Switzerland.31,33 Early
psychosis patients were diagnosed according to DSM-IV criteria after a 3-
years follow-up in the TIPP program (University Hospital Lausanne33,50).
Patients included in the TIPP program had less than 6 months of anti-
psychotic medication. Less female than male patients have been recruited
in this cohort; therefore we focused on men the study of early psychosis
patients. Control subjects were assessed and selected with the Diagnostic
Interview for Genetic Studies. Individuals with a neurological, major mood,
psychotic, or substance-use disorder and a ﬁrst-degree relative with a
psychotic disorder were excluded. All enrolled subjects provided a fully
informed written consent; all procedures, including biopsy, were in
accordance with the ethical standards of the Helsinki Declaration as
revised in 1983, and was approved by the ethical committee of Lausanne
University Hospital on human experimentation.
Culture of ﬁbroblast
Secondary cultures of ﬁbroblasts were established from skin biopsies.31,33
Skin-derived ﬁbroblasts from patients with early psychosis and age-
matched, sex-matched controls were processed in parallel as described
previously.31,33 We could not match for GCLC genotypes as control
individuals with GCLC high-risk genotypes were not frequent enough in
our cohort. After thawing, cells were ampliﬁed in Dulbecco’s Modiﬁed
Eagle Medium (DMEM, Gibco), 2% Ultroser™G (Pall Corp), 1% penicilline-
streptomycine (Gibco). After ﬁve passages, we plated the ﬁbroblasts at
5,104 cells/well (12-wells plate); we treated the cells the day after (18 h of
treatment, 50uM tBHQ (Sigma) or 0.05% dimethylsulfoxide (Sigma) for
vehicle).
Microarray
RNA was puriﬁed with RNAeasy column (Qiagen); quality was checked by
Aligent 2100 bioanalyzer chips. Affymetrix, 1.0ST GeneChips were
processed at Lausanne Genomic Technologies Facility according to
manufacturer recommendation. Hybridization quality was assessed using
the Bioconductor package affy51 in R (http://www.R-project.org; http://
www.Bioconductor.org). Log2 normalized expression signals were calcu-
lated using RMA algorithm52 (comprising background correction, quantile
normalization and probe set summary by robust regression). Sub-sequent
analyses were based on Gene Ontology Annotation (UniProt-GOA).
Fig. 3 Uptake of cystine by OPCs was evaluated after 15min (a) and 30min (b). Three conditions were compared: without shRNA (black),
transduced with a scrambled shRNA (gray), transduced with GCLC knock-down (white). Background level of cystine uptake was evaluated in
the presence of glutamate (red). Data are represented as mean± standard error of the mean (n= 4 per group); *p-value< 0.05
Upregulation of xc- activity in schizophrenia
M Fournier et al.
4
npj Schizophrenia (2017)  31 Published in partnership with the Schizophrenia International Research Society
Primary cultures of glial cells
All animal procedures were approved by the Swiss cantonal veterinary
ofﬁce. Primary glial cells were dissociated from cortex of males and females
Wistar Han rat pups at 3-days postnatal as previously described.34 Cells
were cultured in DMEM, 10% fetal calf serum (FCS), 1% penicillin-
streptomycin at 37 °C, 5% CO2. After 7 days in vitro (DIV), cells were
infected with lentiviruses (multiplicity of infection: 5) to overexpress GCLC
shRNA: GGAGGCTACTTCTATATTA or scrambled shRNA: CTTACAATCA-
GACTGGCGA. Puromycin was added 48 h post-infection (Calbiochem,
1ug/mL). After 10 DIV, oligodendrocytes progenitor cells (OPCs) were
separated from astrocytes and microglia by overnight shaking. OPCs were
plated at 1.2,105 cells/well in 12-wells plate (DMEM, 2.5 uM forskoline
(Calbiochem), 50 ug/ml apotransferrin, 5 ug/ml insulin (Sigma), 30 nM
sodium selenate (Sigma), 10 nM hydrocortisone (Sigma), 10 nM D-biotine
(Sigma), 1 mg/ml bovine serum albumin (Sigma), 10 ng/ml PDGF-AA
(Sigma), 10ng/ml human ﬁbroblast growth factor-basic (Sigma)); experi-
ments were performed 14 DIV. In parallel, astrocytes which remained
attached after shaking were plated at 7.5,104 cells/well in 12-wells plates in
normal culture media (DMEM, 10% FCS, 1% penicillin-streptomycin) or in
differentiation media (DMEM, 2% FCS, 15uM di-butyryl cyclic AMP (Enzo)
for 8 days).
Cystine uptake
Xc- activity was assessed based on previously published protocol.53 Brieﬂy,
cells were washed with Hank’s balanced salt solution pH 7.4 (HBSS; 120
mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 0.1% Glucose, 20 mM
Hepes (Sigma)) and equilibrated in HBSS for 10min at 37 °C, eventually
with transporter inhibitor (sulfasalazine 1 mM (Sigma); glutamate 2.5 mM).
Medium was then changed for uptake buffer (0.5 mM acivicin, 1 mM D-
aspartate, 35uM cystine including 1uCi/mL of 14C-cystine (PerkinElmer) in
HBSS). Uptake was done at 37 °C and terminated on ice by removing
uptake buffer and adding cold phosphate buffer saline (PBS). Cells were
lysed with 500 μL of warm PBS with 0.5% sodium-dodecyl-sulfate.
Incorporated radioactivity was quantiﬁed by liquid scintillation counting
(Tricarb 2900TR Packard). Levels of radioactivity are normalized for protein
content assessed with Bicinchoninic acid assay, the mean of technical
duplicates was calculated. Data presented are representative of two
experimental replications
Statistical analyses
For microarray data, we calculated for each probe set M-values (log base 2
of the fold change between two conditions), moderated t-statistic (ratio of
the M-value to its standard error), p-values derived from moderated t, and
adjusted p-value (FDR, Benjamini–Hochberg step-up procedure). For
uptake experiments, we used student t-test in R on log-transformed data.
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Fig. 4 Uptake of cystine by astrocytes: a Decrease of GCLC mRNA
assessed by quantitative PCR in astrocytes transduced with GCLC
shRNA is expressed as percentage of the condition with scrambled
shRNA. b Uptake of cystine in dividing astrocytes transduced with
scrambled (black) or GCLC shRNA (white). c Uptake of cystine in
dbcAMP-treated astrocytes transduced with scrambled (black) or
GCLC shRNA (white). Data are represented as mean± standard error
of the mean (n= 3 per group); *p-value< 0.05
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